Use of physiologically acceptable vanadium compounds, salts and complexes

Abstract

Use of a physiologically acceptable vanadium compound, salt or complex as active component in the preparation of a pharmaceutical composition for the prophylactic treatment of secondary injury of tissue, said secondary injury being induced by primary injury of mainly surrounding tissue, in particular surrounding tissue, and being the result of a traumatic event.

1 . Use of a physiologically acceptable vanadium compound as active component in the preparation of a pharmaceutical composition for the prophylactic treatment of secundary injury of tissue, said secundary injury being induced by primary injury of mainly surrounding tissue and being the result of a traumatic event.  
     
     
         2 . Use according to  claim 1 , wherein the pharmaceutical composition is administered in a single dose.  
     
     
         3 . Use according to  claim 1  or  claim 2 , wherein the pharmaceutical composition is administered before or immediately or shortly after the traumatic event.  
     
     
         4 . Use according to  claim 3 , wherein the pharmaceutical composition is administered within one week after the traumatic event.  
     
     
         5 . Use according to any one of the preceding claims, wherein the pharmaceutical composition is administered intravenously or orally.  
     
     
         6 . Use according to any one of the preceding claims, wherein the tissue is a transplant.  
     
     
         7 . Use according to any one of the preceding claims, wherein the traumatic event is surgery.  
     
     
         8 . Use according to any one of the preceding claims, wherein the tissue is non-proliferative tissue.  
     
     
         9 . Use according to  claim 8 , wherein the non-proliferative tissue is heart, kidney, liver, nervous or other differentiated tissue.  
     
     
         10 . Use according to  claim 8  or  claim 9 , wherein the traumatic event is ischaemia.  
     
     
         11 . Use according to any one of  claims 1  to  7 , wherein primary injury occurs to epidermal tissue.  
     
     
         12 . Use according to any one of  claims 1  to  5  and  11 , wherein the traumatic event is a burn.  
     
     
         13 . Use according to  claim 12 , wherein the tissue comprises a deep vascular plexus, hair-adnexes and/or sweat glands.  
     
     
         14 . Use according to any one of the preceding claims, wherein the vanadium compound is an organovanadium compound.  
     
     
         15 . Use according to  claim 14 , wherein the vanadium compound is bis(maltolato)oxovanadium(IV) or the corresponding bis(maltolato)oxovanadate salt.